Literature DB >> 23772134

Nodular episcleritis after laser in situ keratomileusis in patient with systemic lupus erythematosus.

Mohammad Al-Amry1.   

Abstract

Entities:  

Year:  2013        PMID: 23772134      PMCID: PMC3678206          DOI: 10.4103/0974-620X.111938

Source DB:  PubMed          Journal:  Oman J Ophthalmol        ISSN: 0974-620X


× No keyword cloud information.
Sir, Laser in situ keratomileusis (LASIK) is safe and efficacious for the treatment of refractive error. However, controversy remains regarding LASIK for patients with autoimmune disorders.[1-3] Episcleritis is a manifestation of systemic lupus erythematosis (SLE), which can be successfully managed by observation and topical lubricants. However, some cases may warrant the use of topical corticosteroids. A 28-year-old female with an established well controlled SLE underwent uneventful bilateral LASIK for myopic astigmatism. A mechanical microkeratome was used to perform the keratectomy. One week post-operatively the patient presented with tearing, moderate pain, and redness in the lateral aspect of her left eye. On examination, her vision was 20/20 and the Slit lamp examination indicated a nodular episcleritis surrounded by engorged episcleral blood vessels [Figure 1]. The posterior segment examination was unremarkable.
Figure 1

Nodular episcleritis 1 week after laser in situkeratomileusis in a patient with well controlled systemic lupus erythematosus

Nodular episcleritis 1 week after laser in situkeratomileusis in a patient with well controlled systemic lupus erythematosus Topical prednisolone acetate 1%, and diclofenac sodium 1%, 4 times a day was started. The episcleritis was completely resolved within 2 weeks and the patient has remained free of systemic or ocular reactivation over the last 3 years [Figure 2].
Figure 2

Complete resolution of episcleritis after topical corticosteroid therapy in a patient with well controlled systemic lupus erythematosus who had undergone laser in situkeratomileusis

Complete resolution of episcleritis after topical corticosteroid therapy in a patient with well controlled systemic lupus erythematosus who had undergone laser in situkeratomileusis Ophthalmic manifestations occur through immune vasculitis and/or thrombosis and immune complex deposition with wide range of clinical presentation including, scleritis and episcleritis.[4] Episcleritis is an acute self-limited inflammation of the episclera that frequently affects young and middle aged individuals. It occurs in association with SLE in one-third of the cases.[4] SLE is a chronic, systemic autoimmune disease, occur 9 times more frequently in typically young, middle-aged women. Some have postulated that estrogens enhance the immune response.[5] LASIK is suitable in well controlled autoimmune disorders such as SLE. Smith and Maloney[1] performed LASIK in 49 eyes of 26 patients with autoimmune diseases, 7 of whom had SLE and reported no complications. We recommend judicious use of topical steroids in cases of episcleritis due to the attendant risks of steroid use. SLE patients have an altered autoimmune system. Even when they are symptom-free, the disease may not be inactive; this makes them susceptible to the risk of post-operative inflammation. This possibility should be explained to the patient pre-operatively.
  5 in total

1.  Episcleritis in childhood.

Authors:  R W Read; A H Weiss; D D Sherry
Journal:  Ophthalmology       Date:  1999-12       Impact factor: 12.079

2.  Excimer laser refractive surgery in autoimmune diseases.

Authors:  Thomas Kohnen
Journal:  J Cataract Refract Surg       Date:  2006-08       Impact factor: 3.351

3.  Severity of episcleritis and systemic disease association.

Authors:  E K Akpek; H S Uy; W Christen; C Gurdal; C S Foster
Journal:  Ophthalmology       Date:  1999-04       Impact factor: 12.079

4.  Laser in situ keratomileusis in patients with autoimmune diseases.

Authors:  Ronald J Smith; Robert K Maloney
Journal:  J Cataract Refract Surg       Date:  2006-08       Impact factor: 3.351

Review 5.  Ocular manifestations of systemic lupus erythematosus.

Authors:  R R Sivaraj; O M Durrani; A K Denniston; P I Murray; Caroline Gordon
Journal:  Rheumatology (Oxford)       Date:  2007-08-05       Impact factor: 7.580

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.